Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply
- PMID: 34973233
- DOI: 10.1016/S1470-2045(21)00723-3
Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply
Conflict of interest statement
FS received financial support from Janssen for the ACIS study, and reports grants or contracts, consulting fees, and payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Myovant, Novartis, and Sanofi, outside of the submitted work. PDP, SB-M, JL, and SAM are employees of Janssen Research and Development and hold stock in Johnson & Johnson. DER has received support from Janssen for the ACIS study, and reports uncompensated participation in advisory boards for AstraZeneca, Bayer, Genentech, Janssen, and Myovant, outside of the submitted work.
Comment on
-
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.Lancet Oncol. 2021 Nov;22(11):1541-1559. doi: 10.1016/S1470-2045(21)00402-2. Epub 2021 Sep 30. Lancet Oncol. 2021. PMID: 34600602 Free PMC article. Clinical Trial.
-
Radiographic progression-free survival in the ACIS trial for prostate cancer.Lancet Oncol. 2022 Jan;23(1):e3. doi: 10.1016/S1470-2045(21)00710-5. Lancet Oncol. 2022. PMID: 34973229 No abstract available.
-
Radiographic progression-free survival in the ACIS trial for prostate cancer.Lancet Oncol. 2022 Jan;23(1):e4. doi: 10.1016/S1470-2045(21)00719-1. Lancet Oncol. 2022. PMID: 34973231 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
